Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: Improved applicability to pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 72, Issue , 2013, Pages 245-250

  Hu, Zhe Yi ^a   Laizure, S Casey ^a   Meibohm, Bernd ^a   Herring, Vanessa L ^a   Parker, Robert B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Electrospray ionization; Liquid chromatography; Mass spectrometry; Oseltamivir; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; DRUG METABOLITE; FLUORIDE SODIUM; OSELTAMIVIR; STABLE ISOTOPE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; NORMAL HUMAN; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; OSELTAMIVIR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84869082065     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.08.029     Document Type: Article

References (20)

1. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high risk patients. J. Antimicrob. Chemother. 2010, 65(Suppl. 2):ii11-ii24.
2. Reddy D. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J. Antimicrob. Chemother. 2010, 65(Suppl. 2):ii35-ii40.
3. Wiltshire H., Wiltshire B., Citron A., Clarke T., Serpe C., Gray D., Herron W. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J. Chromatogr. B 2000, 745:373-388.
4. Lindegardh N., Hanpithakpong W., Wattanagoon Y., Singhasivanon P., White N.J., Day N.P. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J. Chromatogr. B 2007, 859:74-83.
5. Heinig K., Bucheli F. Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2008, 876:129-136.
6. Kanneti R., Bhavesh D., Paramar D., Bhatt S.R.P.A. Development and validation of a high throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. Biomed. Chromatogr. 2011, 25:727-733.
7. Hooff G.P., Meesters R.J., van Kampen J.J., van Huizen N.A., Koch B., Al Hadithy A.F., van Gelder T., Osterhaus A.D., Gruters R.A., Luider T.M. Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate-a validated assay for the clinic. Anal. Bioanal. Chem. 2011, 400:3473-3479.
8. ®) and oseltamivir carboxylate in dried blood spots using offline or online extraction. Bioanalysis 2011, 3:421-437.
9. Kromdijk W., Rosing H., van den Broek M.P., Beijnen J.H., Huitema A.D. Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J. Chromatogr. B 2012, 891-892:57-63.
10. Chang Q., Chow M.S., Zuo Z. Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method. Biomed. Chromatogr. 2009, 23:852-857.
11. Hu Z., Sun Y., Du F., Niu W., Xu F., Huang Y., Li C. Accurate determination of the anticancer prodrug simmitecan and its active metabolite chimmitecan in various plasma samples based on immediate deactivation of blood carboxylesterases. J. Chromatogr. A 2011, 1218:6646-6653.
12. U.S. Food and Drug Administration, Bioanalytical Method Validation, (accessed on May 2012). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf%202001.
13. Gao S., Zhang Z.P., Karnes H.T. Sensitivity enhancement in liquid chromatography/atmospheric pressure ionization mass spectrometry using derivatization and mobile phase additives. J. Chromatogr. B 2005, 825:98-110.
14. Gosetti F., Mazzucco E., Zampieri D., Gennaro M.C. Signal suppression/enhancement in high-performance liquid chromatography tandem mass spectrometry. J. Chromatogr. A 2010, 1217:3929-3937.
15. Trufelli H., Palma P., Famiglini G., Cappiello A. An overview of matrix effects in liquid chromatography-mass spectrometry. Mass Spectrom. Rev. 2011, 30:491-509.
16. Chambers E., Wagrowski-Diehl D.M., Lu Z., Mazzeo J.R. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B 2007, 852:22-34.
17. Churchwell M.I., Twaddle N.C., Meeker L.R., Doerge D.R. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS. J. Chromatogr. B 2005, 825:134-143.
18. Dams R., Benijts T., Gunther W., Lambert W., De Leenheer A. Influence of the eluent composition on the ionization efficiency for morphine of pneumatically assisted electrospray, atmospheric-pressure chemical ionization and sonic spray. Rapid Commun. Mass Spectrom. 2002, 16:1072-1077.
19. Niu W., Zhu X., Yu K., Li L., Sun Y., Li C. Nebulizing conditions of pneumatic electrospray ionization significantly influence electrolyte effects on compound measurement. J. Mass Spectrom. 2012, 47:370-380.
20. He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 1999, 37:471-484.